Cardiff Oncology, Inc. 8-K

What Happened

• Cardiff Oncology, Inc. filed an 8-K dated January 27, 2026, reporting that CEO Dr. Mark Erlander, Ph.D., and CFO James Levine stepped down from their roles as part of a strategic leadership review.
• The Board appointed director Dr. Mani Mohindru as interim Chief Executive Officer. Brigitte Lindsay, formerly Senior Vice President, Finance, was promoted to Chief Accounting Officer.
• On the same day the company issued a press release announcing a positive update from CRDF‑004, a randomized Phase 2 trial of onvansertib combined with standard-of-care regimens (FOLFIRI/bevacizumab or FOLFOX/bevacizumab) in first-line RAS‑mutated metastatic colorectal cancer.

Key Details

• Date of filing/announcements: January 27, 2026.
• Leadership changes: Dr. Mark Erlander (CEO) and James Levine (CFO) stepped down; Dr. Mani Mohindru named interim CEO; Brigitte Lindsay promoted to Chief Accounting Officer.
• Clinical program: Positive update reported from CRDF‑004, a randomized Phase 2 study of onvansertib + SoC in first-line RAS‑mutated mCRC (FOLFIRI/bev or FOLFOX/bev).
• Dr. Mohindru background: experienced biotech executive, founder of Roshon Therapeutics, current board member of CytomX Therapeutics, and former CEO/senior leader at multiple biotech companies.

Why It Matters

• Leadership change is material for investors because CEO and CFO departures can affect strategy, operations and investor confidence; the board installed an experienced biotech executive as interim CEO, which may support continuity.
• Promotion of the company’s SVP Finance to Chief Accounting Officer maintains internal accounting continuity.
• The announced positive CRDF‑004 Phase 2 update is a substantive clinical development for Cardiff’s lead program; investors should watch for full data releases, regulatory implications, and any related forward-looking guidance or financing updates from the company.